Calamos Advisors »

Halozyme Therapeutics Inc Note 1.000 8/1 shares owned by Calamos Advisors

Quarter-by-quarter ownership of Halozyme Therapeutics Inc Note 1.000 8/1 shares owned by Calamos Advisors from 13F filings

Historical chart of Calamos Advisors investment in Halozyme Therapeutics Inc Note 1.000 8/1

Tip: Access up to 7 years of quarterly data

All positions including Halozyme Therapeutics Inc Note 1.000 8/1 held by Calamos Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Halozyme Therapeutics Inc Note 1.000 8/1 by Calamos Advisors

Quarter filed Position value Share count Share price at filing
2024-03-31 $62M 64M 0.98
2023-12-31 $59M 64M 0.93
2023-09-30 $60M 64M 0.94

More positions owned by Calamos Advisors

Microsoft Corporation (MSFT)
NVIDIA Corporation (NVDA)
Apple (AAPL)
Amazon (AMZN)
Alphabet Cap Stk Cl A (GOOGL)
Meta Platforms Cl A (META)
Palo Alto Networks Note 0.375% 6/0 (Principal)
Eli Lilly & Co. (LLY)
Pioneer Nat Res Note 0.250% 5/1 (Principal)
Visa Com Cl A (V)
Spdr S&p 500 Etf Tr Tr Unit (SPY)
Alphabet Cap Stk Cl C (GOOG)
Broadcom (AVGO)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)
UnitedHealth (UNH)

View all positions for Calamos Advisors

Top funds holding Halozyme Therapeutics Inc Note 1.000 8/1

M&g Investment Management
Calamos Advisors
Wolverine Asset Management
MacKay Shields
Citadel Advisors
Polar Securities
Millennium Management
Bank Of Montreal
Kohlberg Kravis Roberts & Co
D. E. Shaw & Co
Absolute Investment Advisers
Leucadia National Corporation
SSI Investment Management
CSS
Readystate Asset Management

View all funds holding Halozyme Therapeutics Inc Note 1.000 8/1